Send to

Choose Destination
J Infect Dis. 2013 Aug 1;208(3):468-78. doi: 10.1093/infdis/jit171. Epub 2013 Apr 18.

Expression in yeast links field polymorphisms in PfATP6 to in vitro artemisinin resistance and identifies new inhibitor classes.

Author information

Division of Clinical Sciences, St. George's, University of London, UK.



The mechanism of action of artemisinins against malaria is unclear, despite their widespread use in combination therapies and the emergence of resistance.


Here, we report expression of PfATP6 (a SERCA pump) in yeast and demonstrate its inhibition by artemisinins. Mutations in PfATP6 identified in field isolates (such as S769N) and in laboratory clones (such as L263E) decrease susceptibility to artemisinins, whereas they increase susceptibility to unrelated inhibitors such as cyclopiazonic acid. As predicted from the yeast model, Plasmodium falciparum with the L263E mutation is also more susceptible to cyclopiazonic acid. An inability to knockout parasite SERCA pumps provides genetic evidence that they are essential in asexual stages of development. Thaperoxides are a new class of potent antimalarial designed to act by inhibiting PfATP6. Results in yeast confirm this inhibition.


The identification of inhibitors effective against mutated PfATP6 suggests ways in which artemisinin resistance may be overcome.


Artemisinins; PfATP6; Plasmodium falciparum; cyclopiazonic acid; desferioxamine; drug resistance; malaria; thaperoxides; yeast

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center